Skip to main content
Premium Trial:

Request an Annual Quote

Scotland Launches Biopark with Donated MSD Labs

NEW YORK (GenomeWeb News) – The Scottish central lowland region has boosted its available space for hosting life sciences companies after MSD, which operates in the US and Canada as Merck, donated a research facility to house BioCity Scotland, a joint life sciences biopark and incubator venture run by BioCity Nottingham and the Roslin BioCentre.

Located between Glasgow and Edinburgh, the facility in Newhouse, Lanarkshire will provide over 130,000 square feet of labs on a 23 acre site that will house and support bioscience, pharmaceutical, medical technology, and healthcare companies.

BioCity Scotland provides research and development facilities, including processing, storage, equipment, business, and financial support to start-up companies.

"BioCity Scotland is much more than a property proposition — it will be a unique, vibrant community of scientific companies," BioCity Scotland Chairman Louis Nisbet said in a statement.

"The ongoing commercial operation of the site will attract investment to the local area generating employment opportunities for local communities and the success of this development will play a significant role in securing the future of Life Sciences in Scotland," added Chris Hill, MSD VP and former head of the MSD Newhouse facility.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.